SCHEDULE 13G/A: Vanguard Group Discloses 4.60% Passive Stake in Aclaris Therapeutics Inc.
Beneficial Ownership Disclosure
The Vanguard Group has filed an amended Schedule 13G, reporting a 4.60% passive ownership stake in Aclaris Therapeutics Inc. as of March 31, 2025.
Summary
- The Vanguard Group reported beneficial ownership of 4,970,254 shares of Aclaris Therapeutics Inc. common stock.
- This ownership represents 4.60% of the total class of Aclaris Therapeutics Inc. common stock.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment purpose.
- The Vanguard Group holds sole dispositive power over 4,924,774 shares and shared dispositive power over 45,480 shares.
- The Vanguard Group reported no sole or shared voting power over these shares.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of a passive ownership stake by a large institutional investor, providing no direct positive or negative sentiment regarding the issuer's performance or operational status.
Future Outlook
The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure by a large institutional asset manager, The Vanguard Group, detailing its passive investment stake in Aclaris Therapeutics Inc., a common practice for diversified investment firms across various industries.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure of Aclaris Therapeutics Inc. by a significant institutional investor.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement |
| 04/30/2025 | Date of filing |
Keywords
Aclaris Therapeutics, Vanguard Group, Schedule 13G, Common Stock, Passive Investment, Institutional Ownership, SEC Filing, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.